Physical Address
304 North Cardinal St.
Dorchester Center, MA 02124
SELLAS Life Sciences CEO Angelos Stergiou says his company is already one step away from a finalized leukemia vaccine, but another breakthrough – personalized cancer vaccines – could be on the horizon, thanks to artificial intelligence.
“I think this is going to be a revolutionary decade in medicine and clinical research,” he said Thursday at the “Fox & Friends.”
“Where AI comes into play is where it will allow us to do things expeditiously, and it will be more personalized. In other words, if you have a patient with cancer, we can use AI for genomic sequencing and, with the results, we can either create a specific vaccine or treatment, or we can say that that specific treatment will work on the patient.”
DESIGNED AIJEK FOR INFLAMMATORY BOWEL DISEASE ENTERS HUMAN CLINICAL TRIALS: ‘SIGNIFICANT NEED’
Artificial intelligence is expected to revolutionize cancer treatment in the next few years. (iStock)
How long will it take to develop the technology? Stergiou predicts that the first specialized vaccines could arrive in the next three to four years.
“It’s very important to understand that if you put garbage into this algorithm, you’re going to get garbage out, so it’s going to take a lot of work for the medical community to really fit that dataset appropriately, and that’s going to be an ongoing evolutionary thing.”
AI expert and “Some Future Day” author Mark Beckman, who also joined “Fox & Friends” on Thursday, calls the AI revolution “the age of imagination.”
AI COULD PREDICT WHETHER CANCER TREATMENT WILL WORK, EXPERTS SAY: ‘EXCITING TIMES IN MEDICINE’
Addressing the hosts on a curved couch, he noted Google’s new AI research system, AMIE, which is designed to help find rare diseases and serve as a co-pilot for doctors.
“They’ve done some research and the ability to detect these rare diseases and diseases are at a very high level now, so doctors will use this as a tool to help them diagnose.”
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
